Stay updated on Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page.

Latest updates to the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a minor metadata update with no changes to study information.SummaryDifference0.1%

- Check39 days agoChange DetectedAdds explicit institution names (Moffitt Cancer Center and Research Institute) and a 'Helpful Links Provided by' section to the study page, clarifying sponsorship and related resources.SummaryDifference0.2%

- Check53 days agoChange DetectedDeleted footer elements include the Moffitt sponsor attribution and the Helpful Links section. This reduces visibility of institutional affiliation and access to related resources on the study page.SummaryDifference0.2%

- Check60 days agoChange DetectedRevision: v3.4.2 was added and the previous funding-status notice (Revision: v3.4.1) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check67 days agoChange DetectedA government funding notice has been added to the page, and the revision version updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page.